Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles

The nerve growth factor (NGF) is essential for the survival of both peripheral ganglion cells and central cholinergic neurons in the basal forebrain. The accelerated loss of central cholinergic neurons during Alzheimer’s disease may be a determinant cause of dementia, and this observation may suggest a possible therapeutic benefit from treatment with NGF. In recent years, convincing data have been published involving neurotrophic factors for the modulation of dopaminergic transmission within the brain and concerning the ability of NGF to prevent the degeneration of dopaminergic neurons. In this connection, the administration of NGF may slow down the progression of Parkinson’s disease. However, NGF, as well as other peptidic neurotrophic factors, does not significantly penetrate the blood–brain barrier (BBB) from the circulation. Therefore, any clinical usefulness of NGF as a potential CNS therapy will depend on the use of a suitable carrier system that enhances its transport through the BBB. The present study investigates brain delivery of NGF adsorbed on poly(butyl cyanoacrylate) (PBCA) nanoparticles coated with polysorbate 80 and the pharmacological efficacy of this delivery system in the model of acute scopolamine-induced amnesia in rats as well as in the model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian syndrome. As shown by the passive avoidance reflex (PAR) test, the intravenous administration of the nanoparticle-bound NGF successfully reversed scopolamine-induced amnesia and improved recognition and memory. This formulation also demonstrated a significant reduction of the basic symptoms of Parkinsonism (oligokinesia, rigidity, tremor). In addition, the efficient transport of NGF across the BBB was confirmed by direct measurement of NGF concentrations in the murine brain. These results demonstrate that the PBCA nanoparticles coated with polysorbate 80 are an effective carrier system for the transport of NGF to the central nervous system across the BBB following intravenous injection. This approach may improve the NGF-based therapy of age-related neurodegenerative diseases.

[1]  L. Buée,et al.  Neurotrophic factors in Alzheimer’s disease: role of axonal transport , 2008, Genes, brain, and behavior.

[2]  J. Kreuter,et al.  Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Papavassiliou,et al.  Targeting the nerve growth factor network in Alzheimer’s disease , 2007, Expert opinion on investigational drugs.

[4]  F. Mashayekhi,et al.  Infusion of anti‐nerve growth factor into the cisternum magnum of chick embryo leads to decrease cell production in the cerebral cortical germinal epithelium , 2007, European journal of neurology.

[5]  R. Müller,et al.  Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[6]  U. Bonuccelli,et al.  New pharmacologic horizons in the treatment of Parkinson disease , 2006, Neurology.

[7]  J. Kreuter.  Nanoparticles as Drug Delivery Systems for the Brain , 2006 .

[8]  S. Allen,et al.  Clinical relevance of the neurotrophins and their receptors. , 2006, Clinical science.

[9]  L. Maffei,et al.  Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  William A Banks,et al.  Blood-brain barrier transport of cytokines: a mechanism for neuropathology. , 2005, Current pharmaceutical design.

[11]  L. N. Aksenova,et al.  [The effect of long-term administration of isatin and himantan to mice on sensitivity of brain monoamine oxidase B to inhibition by deprenyl in vivo and in vitro]. , 2004, Biomeditsinskaia khimiia.

[12]  J. Schulz,et al.  Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation , 2004, Cell and Tissue Research.

[13]  K. Geiger,et al.  Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.

[14]  D J Begley,et al.  Understanding and circumventing the blood‐brain barrier , 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[15]  K. Mohanakumar,et al.  D‐deprenyl protects nigrostriatal neurons against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurotoxicity , 2003, Synapse.

[16]  K. Shin‐ya,et al.  Divergence in Signaling Pathways Involved in Promotion of Cell Viability Mediated by bFGF, NGF, and EGF in PC12 Cells , 2003, Neurochemical Research.

[17]  A. Cuadrado,et al.  Nerve Growth Factor Protects against 6-Hydroxydopamine-induced Oxidative Stress by Increasing Expression of Heme Oxygenase-1 in a Phosphatidylinositol 3-Kinase-dependent Manner* , 2003, The Journal of Biological Chemistry.

[18]  J. Kreuter,et al.  [Drug delivery to the brain with nanoparticles]. , 2003, Eksperimental'naia i klinicheskaia farmakologiia.

[19]  W. Tyler,et al.  The Role of Neurotrophins in Neurotransmitter Release , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[20]  E. Peskind,et al.  Pharmacologic treatments of dementia. , 2002, The Medical clinics of North America.

[21]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[22]  D D Allen,et al.  Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.

[23]  Zhang Cy,et al.  Pharmacological actions of nerve growth factor-transferrin conjugate on the central nervous system. , 2001 .

[24]  M. Vila,et al.  The role of glial cells in Parkinson's disease , 2001, Current opinion in neurology.

[25]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[26]  K. Shimoke,et al.  Nerve growth factor prevents 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced cell death via the Akt pathway by suppressing caspase‐3‐like activity using PC12 cells: Relevance to therapeutical application for parkinson's disease , 2001, Journal of neuroscience research.

[27]  R. Löbenberg,et al.  Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrier in vivo and in vitro , 2001, Journal of drug targeting.

[28]  G. Siegel,et al.  Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain , 2000, Brain Research Reviews.

[29]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[30]  D. Rohrer,et al.  Promoter-activated expression of nerve growth factor for treatment of neurodegenerative diseases , 1999, Gene Therapy.

[31]  R. Cruz-Aguado,et al.  [Nerve growth factor: possibilities and limitations of its clinical application]. , 1999, Revista de neurologia.

[32]  W. Oertel,et al.  Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro , 1999, Neuroscience Letters.

[33]  C. Sortwell,et al.  Therapeutic Potential of Nerve Growth Factors in Parkinson’s Disease , 1999, Drugs & aging.

[34]  E. Hirsch,et al.  Dopaminergic neurons degenerate by apoptosis in Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[35]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[36]  C. Sirrenberg,et al.  Neurotrophins Stimulate the Release of Dopamine from Rat Mesencephalic Neurons via Trk and p75Lntr Receptors* , 1996, The Journal of Biological Chemistry.

[37]  F. Gage,et al.  Nerve Growth Factor Delivery by Gene Transfer Induces Differential Outgrowth of Sensory, Motor, and Noradrenergic Neurites after Adult Spinal Cord Injury , 1996, Experimental Neurology.

[38]  U. Berger,et al.  Effects of carbon dioxide-induced anesthesia on cholinergic parameters in rat brain. , 1994, Laboratory animal science.

[39]  C. Ríos,et al.  Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice , 1992, Neurochemical Research.

[40]  J. Rinne,et al.  Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra , 1989, Annals of neurology.

[41]  Yves-Alain Barde,et al.  Trophic factors and neuronal survival , 1989, Neuron.

[42]  H. Pakkenberg,et al.  The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, The New England journal of medicine.

[43]  F. Hefti.  Is Alzheimer disease caused by lack of nerve growth factor? , 1983, Annals of neurology.

[44]  P. Couvreur,et al.  Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties , 1979, The Journal of pharmacy and pharmacology.

[45]  V. Labhasetwar,et al.  Nanosystems in Drug Targeting: Opportunities and Challenges , 2005 .

[46]  C. Y. Zhang,et al.  Pharmacological actions of nerve growth factor-transferrin conjugate on the central nervous system. , 2001, Journal of natural toxins.

[47]  B. Ferger,et al.  Neurochemical findings in the MPTP model of Parkinson's disease , 2001, Journal of neural transmission.

[48]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[49]  D. A. Kharkevich,et al.  Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles , 1995 .

[50]  Mosharrof Ah,et al.  Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice). , 1988 .

[51]  V. Petkov,et al.  Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice). , 1988, Acta physiologica et pharmacologica Bulgarica.

[52]  I. Amende,et al.  Journal of Neuroengineering and Rehabilitation Open Access Gait Dynamics in Mouse Models of Parkinson's Disease and Huntington's Disease Gait Variabilitygaitmouse Modelsneurodegenerationmovement Disordersamyotrophic Lateral Sclerosissod1 , 2022 .